Skip to main content
. Author manuscript; available in PMC: 2009 Feb 6.
Published in final edited form as: J Ocul Pharmacol Ther. 2008 Feb;24(1):104–115. doi: 10.1089/jop.2007.0074

FIG. 3.

FIG. 3

Effect on intraocular pressure of CB1 antagonist, SR141716, followed by WIN55212-2. CB1 antagonist, SR141716, was applied topically 30 min (see arrow) prior to the administration of WIN55212-2 (t = 0 min). Data are presented as mean ± standard error of the mean. *Significantly reduced from baseline (t = 0), P < 0.05. †Significantly greater than 1.0% WIN55212-2 alone treatment (P < 0.05).